Sanford D. Markowitz

Sanford D. Markowitz

Auto-generated profile, based on publicly available information

Sanford D. Markowitz

Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, OH, USA; Department of Medicine, Case Western Reserve University, Cleveland, OH, USA; Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 December 2009 in New England Journal of Medicine
Verified
Journal Article
Closed access
SMSanford D. Markowitz
Sanford D. Markowitz
MBMonica M. Bertagnolli
Monica M. Bertagnolli
This review gives an account of recent advances in our knowledge of the molecular mechanisms in colorectal cancer. Genetic changes in the germ line, combined with somatic mutations, occur in familial syndromes of colorectal cancer, whereas somatic mutations are the outstanding feature of sporadic colorectal cancer. Genetic changes drive the progression from adenoma to carcinoma and probably influence individual susceptibility and response to treatment.

18 March 2008 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
SJSiân Jones
Siân Jones
WCWei-Dong Chen
Wei-Dong Chen
GPGiovanni Parmigiani
Giovanni Parmigiani
FDFrank Diehl
Frank Diehl
NBNiko Beerenwinkel
Niko Beerenwinkel
SMSanford D. Markowitz
Sanford D. Markowitz
We show that the times separating the birth of benign, invasive, and metastatic tumor cells can be determined by analysis of the mutations they have in common. When combined with prior clinical observations, these analyses suggest the following general conclusions about colorectal tumorigenesis: ( i ) It takes ≈17 years for a large benign tumor to evolve into an advanced cancer but <2 years for cells within that cancer to acquire the ability to metastasize; ( ii ) it requires few, if any, selective events to transform a highly invasive cancer cell into one with the capacity to metastasize; ( iii ) the process of cell culture ex vivo does not introduce new clonal mutations into colorectal tumor cell populations; and ( iv ) the rates at which point mutations develop in advanced cancers are similar to those of normal cells. These results have important implications for understanding human tumor pathogenesis, particularly those associated with metastasis.

28 July 2008 in Genes, Chromosomes and Cancer
Verified
Journal Article
Closed access
PDF file
CGChunguang Guo
Chunguang Guo
JSJerome F. Sah
Jerome F. Sah
LBLydia Beard
Lydia Beard
JWJames K. V. Willson
James K. V. Willson
SMSanford D. Markowitz
Sanford D. Markowitz
KGKishore Guda
Kishore Guda

3 August 2005 in JNCI: Journal of the National Cancer Institute
Verified
Journal Article
Open access
PDF file
WCWei-Dong Chen
Wei-Dong Chen
ZHZ. James Han
Z. James Han
JSJoel Skoletsky
Joel Skoletsky
JOJeff Olson
Jeff Olson
JSJerome Sah
Jerome Sah
SMSanford D. Markowitz
Sanford D. Markowitz
Background: Increased DNA methylation is an epigenetic alteration that is common in human cancers and is often associated with transcriptional silencing. Aberrantly methylated DNA has also been proposed as a potential tumor marker. However, genes such as vimentin, which are transcriptionally silent in normal epithelium, have not until now been considered as targets for cancer-associated aberrant methylation and for use as cancer markers. Methods: We applied methylation-specific polymerase chain reaction to the vimentin gene, which is transcriptionally silent in normal colonocytes, and compared methylation of vimentin exon 1 in cancer tissues and in fecal DNA from colon cancer patients versus control samples from healthy subjects. Results: Vimentin exon-1 sequences were unmethylated in 45 of 46 normal colon tissues. In contrast, vimentin exon-1 sequences were methylated in 83% (38 of 46) and 53% (57 of 107) of tumors from two independently collected groups of colon cancer patients. When evaluated as a marker for colon cancer detection in fecal DNA from another set of colon cancer patients, aberrant vimentin methylation was detected in fecal DNA from 43 of 94 patients, for a sensitivity of 46% (95% confidence interval [CI] = 35% to 56%). The sensitivity for detecting stage I and II cancers was 43% (26 of 60 case patients) (95% CI = 31% to 57%). Only 10% (20 of 198 case patients) of control fecal DNA samples from cancer-free individuals tested positive for vimentin methylation, for a specificity of 90% (95% CI = 85% to 94%). Conclusions : Aberrant methylation of exon-1 sequences within the nontranscribed vimentin gene is a novel molecular biomarker of colon cancer and can be successfully detected in fecal DNA to identify nearly half of individuals with colon cancer.

16 August 2009 in Nature Biotechnology
Verified
Journal Article
Closed access
PDF file
MLMeng Li
Meng Li
WCWei-Dong Chen
Wei-Dong Chen
NPNickolas Papadopoulos
Nickolas Papadopoulos
SGSteven N Goodman
Steven N Goodman
NBNiels Christian Bjerregaard
Niels Christian Bjerregaard
BVBert Vogelstein
Bert Vogelstein

12 June 2015 in Science
Verified
Journal Article
Closed access
PDF file
YZYongyou Zhang
Yongyou Zhang
ADAmar Desai
Amar Desai
SYSung Yeun Yang
Sung Yeun Yang
KBKi Beom Bae
Ki Beom Bae
MAMonika I. Antczak
Monika I. Antczak
SMSanford D. Markowitz
Sanford D. Markowitz
A shot in the arm for damaged tissue: Tissue damage can be caused by injury, disease, and even certain medical treatments. There is great interest in identifying drugs that accelerate tissue regeneration and recovery, especially drugs that might benefit multiple organ systems. Zhang et al. describe a compound with this desired activity, at least in mice (see the Perspective by FitzGerald). SW033291 promotes recovery of the hematopoietic system after bone marrow transplantation, prevents the development of ulcerative colitis in the intestine, and accelerates liver regeneration after hepatic surgery. It acts by inhibiting an enzyme that degrades prostaglandins, lipid signaling molecules that have been implicated in tissue stem cell maintenance. Science , this issue 10.1126/science.aaa2340 ; see also p. 1208